Cabozantinib Malate
|
|
Cabozantinib Malate 속성
- 녹는점
- 166-169°C
- 저장 조건
- Sealed in dry,Room Temperature
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨, 가열), 피리딘(약간 용해됨)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 색상
- 흰색에서 황백색까지
- InChIKey
- HFCFMRYTXDINDK-NJXVLOPVNA-N
- SMILES
- [C@@H](O)(C(=O)O)CC(=O)O.C(C1(CC1)C(=O)NC1C=CC(F)=CC=1)(=O)NC1C=CC(OC2=CC=NC3C=C(OC)C(OC)=CC2=3)=CC=1 |&1:0,r|
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
그림문자(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Danger | |||||||||||||||||||||||||||||||||||
유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
예방조치문구: |
|
Cabozantinib Malate C화학적 특성, 용도, 생산
개요
Cabozantinib S-MALATE,formerly known as XL184, trade name Cabometyx, is developed by Exelixis biopharmaceutical company in the United States. The drug is mainly targeted at MET and VEGFR2 tyrosine kinases that associated with the growth and proliferation of prostate cancer, inhibiting tumor metastasis and angiogenesis. Cabozantinib S-MALATE , the malate of Cabozantinib, is an effective VEGFR2 inhibitor, and IC50 is 0.035 nM. It also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2 and AXL, and IC50 is 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM respectively.Cabozantinib(Cometriq) was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib(Cometriq) is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.
화학적 성질
Cabozantinib (S)-malate salt is a white to off-white solid that is practically insoluble in aqueous media.용도
Cabozantinib malate is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.정의
ChEBI: Cabozantinib malate is a malate salt that is the mono-(S)-malate salt of cabozantinib. A multi-tyrosine kinase inhibitor, used for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor, an antineoplastic agent and a prodrug. It contains a cabozantinib.Clinical Use
Cabozantinib (S)-malate (Cometriq®), which was discovered and developed by Exelixis, gained approval by the U.S. FDA in November 2012. The drug’s indication is for the treatment of medullary thyroid cancer (MTC), and is the second drug for this disease after AstraZeneca’s vandetanib (Caprelsa®). The drug was successfully launched on January 24, 2013. Cabozantinib inhibits multiple receptor tyrosine kinases including RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2. It is currently also undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.주의 사항
Cometriq has a boxed warning that increases the incidence of gastrointestinal perforation and fistulaFormation and severe bleeding. If you have severe stomach pain, or if you feel that you are suffocating and vomiting while eating or drinking, call your doctor. Warnings and precautions include thrombosis events, Wound complications, hypertension, jaw osteonecrosis, palm-toe erythema paresthesia Syndrome (PPES), proteinuria and reversible posterior leukoencephalopathy syndrome (RPLS).
참고 문헌
[1] yakes f m, chen j, tan j, et al. cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. molecular cancer therapeutics, 2011, 10(12): 2298-2308. DOI:10.1158/1535-7163.MCT-11-0264[2] zhang y, guessous f, kofman a, et al. xl-184, a met, vegfr-2 and ret kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and nsclc. idrugs, 2010, 13(2): 112. PMCID:PMC3268517
Cabozantinib Malate 준비 용품 및 원자재
원자재
준비 용품
Cabozantinib Malate 공급 업체
글로벌( 340)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 |
admin@ahdchem.com | China | 297 | 58 |
HangZhou RunYan Pharma Technology Co.,LTD. | +8618882027439 |
sales2@runyanpharma.com | China | 304 | 58 |
Jinan Good Medical Technology Co.,Ltd | +86-53155562571 +86-008613553167512 |
13553167512@139.com | China | 23 | 58 |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 |
sales@sjar-tech.com | China | 297 | 58 |
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Ltd. | +86-0311-67591193 +8613931880626 |
sales02@dingminpharma.com | China | 252 | 58 |
SICHUAN XIELI PHARMACEUTICAL CO.,LTD. | +86-028-60118998 +8615830127659 |
sales7@xielipharm.com | China | 31 | 58 |
Hebei Yanxi Chemical Co., Ltd. | +8617531190177 |
peter@yan-xi.com | China | 5873 | 58 |
Changzhou waston chemical technology Co.,Ltd | +86-051985861892 +8618112881323 |
info@wastonchem.com | China | 250 | 58 |
Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8617865335152 |
Mandy@hangyubiotech.com | China | 10991 | 58 |
Shanghai Daken Advanced Materials Co.,Ltd | +86-371-66670886 |
info@dakenam.com | China | 18628 | 58 |
Cabozantinib Malate 관련 검색:
4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline
1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid
Alectinib Hydrochloride
PLX4032
Nintedanib Ethanesulfonate Salt
Crizotinib
Afatinib (BIBW 2992)
PLERIXAFOR
SOLITHROMYCIN
Afatinib dimaleate
Dacomitinib (PF299804)
Neratinib
Cyclopropanecarboxylic acid, 1-[[(2-fluorophenyl)amino]carbonyl]-
Cabozantinib impurity 1DYH
1,1-Cyclopropanedicarboxamide, N,N'-bis[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-
Cyclopropanecarboxylic acid, 1-[(phenylaMino)carbonyl]-
Quinoline, 6,7-dimethoxy-4-(4-nitrophenoxy)-
1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-phenyl-